Evidence library.

Combined medical therapy in allergic rhinitis: systematic review and meta-analysis

53 randomized controlled trials · Systematic review and meta-analysis

Combinations (INCS plus intranasal antihistamine; antihistamine plus decongestant) outperform monotherapy on nasal and ocular symptoms and quality of life.

Azelastine plus fluticasone in a single device; 52-week safety (MP29-02 / Berger 2014)

Berger 2014, n=612 · Randomized controlled trials and long-term safety study

The combination achieved markedly greater TNSS reduction than either monotherapy, with comparable safety over 52 weeks.

Citation on file

Triamcinolone acetonide aqueous nasal spray for perennial allergic rhinitis

1995, n=178 · Multicenter, randomized, double-blind, placebo-controlled

Significant improvement in stuffiness, sneezing, and discharge; onset within days; well tolerated.

Azelastine nasal spray: pharmacology and clinical efficacy in allergic and vasomotor rhinitis

Review · Pharmacology and efficacy review

Rapid onset and prolonged effect; effective in allergic and vasomotor rhinitis, with meaningful decongestant activity uncommon among antihistamines.

Citation on file

Ipratropium bromide for rhinorrhea in perennial rhinitis; long-term 0.06% data

Multiple trials · Randomized controlled trials

Targeted control of watery rhinorrhea through an independent anticholinergic mechanism, including long-term use.

Citation on file

Fluticasone reverses oxymetazoline-induced tachyphylaxis and rebound congestion

Vaidyanathan 2010, Am J Respir Crit Care Med · Randomized, double-blind crossover

After oxymetazoline-induced tachyphylaxis, three days of added fluticasone reversed it (PNIF +45 L/min; curve shift +26.2 L/min, p < 0.001); the effect localized to alpha-1 receptors.

Oxymetazoline adds to the effectiveness of fluticasone furoate in allergic rhinitis

Baroody 2011, J Allergy Clin Immunol, n=60 · Randomized, double-blind, placebo-controlled

Fluticasone furoate plus oxymetazoline beat fluticasone alone, with no rhinitis medicamentosa in any arm over four weeks and none two weeks post-treatment.

Oxymetazoline plus intranasal steroid in chronic rhinitis

Thongngarm 2016, Asian Pac J Allergy Immunol · Randomized controlled trial

Adding oxymetazoline to INCS plus cetirizine improved congestion (p = 0.034) with no rebound two weeks after discontinuation.

Is adding intranasal oxymetazoline to intranasal corticosteroids beneficial in rhinitis?

Fisher & Fishman 2022, 838 patients · Systematic review

Across the literature, concurrent INCS with oxymetazoline does not produce rebound. The safety conclusion is now review-level.

Citation on file

Nasal resistance and CPAP failure

Sugiura 2007, Saitama Medical University · Clinical study

Each 0.1 Pa/cm³/s increase in nasal resistance was associated with 1.48x higher odds of CPAP failure. Association, not an Allermi outcome.

Citation on file

Nasal treatment and CPAP acceptance (as cited internally)

Camacho 2015 · Meta-analysis

Improved CPAP acceptance following nasal treatment in the pooled data. Establishes the nasal airway as a recognized lever in the literature.

Citation on file

Intranasal corticosteroid plus oxymetazoline restoring PAP tolerance (case report)

Anokwute 2025, JCSM · Case report

A published case in which intranasal corticosteroid plus oxymetazoline restored PAP tolerance, closely matching Allermi's formulation. Presented as a case report, not proof of population effect.

Citation on file

Nasal irrigation as an adjunctive treatment in allergic rhinitis: meta-analysis

10 RCTs, 400+ participants · Systematic review and meta-analysis

Saline irrigation produced a 27.7% improvement in nasal symptoms and a 62.1% reduction in medication consumption, well tolerated.

Citation on file